The Effects of Short-term Preoperative Treatment With Hormonal Therapy on Gene Profiles in Breast Cancer

Condition:   Breast Cancer Interventions:   Drug: Tamoxifen Citrate;   Drug: Letrozole;   Drug: Exemestane;   Diagnostic Test: Blueprint;   Diagnostic Test: Mammaprint Sponsors:   Johns Hopkins University;   Agendia Recruiting
Source: - Category: Research Source Type: clinical trials

Related Links:

ConclusionsIn this cohort of young women, population-based cancer registry data on chemotherapy receipt was reasonably accurate and complete in comparison with insurance claims. Radiation and hormone therapy appeared to be less complete.
Source: Cancer Epidemiology - Category: Cancer & Oncology Source Type: research
Abstract The addition of adjuvant chemotherapy to hormonal therapy is often considered questionable in patients with estrogen receptor-positive early breast cancer. Low risk of disease relapse after endocrine treatment alone and/or a low sensitivity to chemotherapy are reasons behind not all patients benefit from chemotherapy. Most of patients could be exposed to unnecessary treatment-related adverse events and health care costs when treatment decision-making is based only on classical clinical histological features. Gene expression profile has been developed to refine physician decision-making process and to tayl...
Source: Current Medicinal Chemistry - Category: Chemistry Authors: Tags: Curr Med Chem Source Type: research
This study aims to evaluate the antitumour activity of tamoxifen (TAM), a major agent of hormonal therapy for breast cancer, in preclinical GBC model. Quantitative real-time PCR was used to investigate mRNA levels. Protein expression was measured by immunohistochemistry and Western blot. Glycolytic levels were measured by glucose consumption and lactic acid measurement. The antitumour activity of TAM alone or with cisplatin was examined with CCK8 assay, colony formation, flow cytometry and in vivo models. The results revealed that ERÉ‘ expression was higher in GBC tissues and predicted poor clinical outcomes. TAM was showe...
Source: J Cell Mol Med - Category: Molecular Biology Authors: Tags: J Cell Mol Med Source Type: research
Authors: Ota S, Tokizaki T, Sugimoto M, Ochiai R, Haruyama T, Ishihara M, Natsume M, Fukasawa Y, Sakamoto T, Tanzawa S, Usui R, Honda T, Ichikawa Y, Watanabe K, Kawano H, Seki N Abstract We herein report a case of breast cancer in a 74-year-old woman treated with exemestane as fourth-line hormonal therapy and bone-modifying agents for long time. She suddenly developed a right femoral shaft fracture during treatment. Her femoral fracture had a beaking sign on radiogram. Given this finding, her fracture was ultimately diagnosed as atypical femoral fracture (AFF). In this case, it was difficult to recognize the differ...
Source: Internal Medicine - Category: Internal Medicine Tags: Intern Med Source Type: research
Authors: Abstract Elevated risk persists more than a decade after stopping hormone therapy. PMID: 31764035 [PubMed - in process]
Source: The American Journal of Nursing - Category: Nursing Tags: Am J Nurs Source Type: research
Elevated risk persists more than a decade after stopping hormone therapy.
Source: AJN - Category: Nursing Tags: In the News Source Type: research
CONCLUSION: Our nationwide retrospective analysis revealed that pregnancy after BC diagnosis was associated with lower mortality than that of nonpregnant patients with BC at a similar age, year at diagnosis, and clinical characteristics. IMPLICATIONS FOR PRACTICE: This article provides high-level evidence based on an Asian population for pregnancy counseling after a breast cancer diagnosis, including for patients with estrogen receptor-positive cancers. The study also revealed the optimal time for patients who would like to become pregnant after breast cancer. PMID: 31767794 [PubMed - as supplied by publisher]
Source: The Oncologist - Category: Cancer & Oncology Authors: Tags: Oncologist Source Type: research
Abstract Experimental and clinical evidence demonstrate that progesterone hormone and its nuclear receptor, the Progesterone Receptor (PR), play critical role in controlling mammary gland tumorigenesis and breast cancer development. Hormonal therapy (Tomaxifen) is the frontline treatment for hormone-dependent breast cancers .Progesterone hormone induces its action on the target cells by binding with its Progesterone receptor (PgR) therefore any genetic variations, which might induce alienation in the progesterone receptor, can result to an increased susceptibility to gynecological cancers. Alu insertion (PROGINS) ...
Source: Endocrine, Metabolic and Immune Disorders Drug Targets - Category: Endocrinology Authors: Tags: Endocr Metab Immune Disord Drug Targets Source Type: research
The recent report by Buszek et  al reassuringly reveals equivalent 5-year overall survival among older patients with breast cancer who have undergone lumpectomy and are receiving adjuvant monotherapy, whether with radiation therapy (RT) or hormone therapy (HT).1 This contribution is consistent with prior efforts in favorable sub populations for which disease-specific outcomes are excellent, remaining life expectancy is limited, and the survival benefit of any adjuvant treatment remains notoriously elusive.
Source: International Journal of Radiation Oncology * Biology * Physics - Category: Radiology Authors: Tags: Comment Source Type: research
AbstractPurpose of ReviewThe goal of the review is to assess the appropriateness of menopausal hormone therapy (MHT) for the primary prevention of bone loss in women at elevated risk in the early years after menopause.Recent FindingsEstrogen alone or combined with progestin to protect the uterus from cancer significantly reduces the risk of osteoporosis-related fractures. MHT increases type 1 collagen production and osteoblast survival and maintains the equilibrium between bone resorption and bone formation by modulating osteoblast/osteocyte and T cell regulation of osteoclasts. Estrogens have positive effects on muscle an...
Source: Current Osteoporosis Reports - Category: Orthopaedics Source Type: research
More News: Breast Cancer | Cancer | Cancer & Oncology | Genetics | Hormonal Therapy | Hormones | Research